Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thibaut Reverdy1, Max Gau1, Andy Karabajakian1

  • 1Centre de lutte contre le cancer Léon-Bérard, Département d'oncologie médicale, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026
Same author

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study.

Head & neck·2026
Same author

Strengthening the foundations of shared decision-making in oncology: Systematic review and formal representation of theoretical models.

Patient education and counseling·2026
Same author

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Cancer chemotherapy and pharmacology·2026
Same author

Refining adjuvant radiation therapy decision using a nomogram in major salivary gland carcinoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunotherapy, including checkpoint inhibitors (anti PD-1/PD-L1), offers survival benefits for recurrent or metastatic head and neck cancer. Biomarkers are crucial for identifying patients most likely to respond to these treatments.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Head and neck cancers are increasingly being treated with immunotherapy.
  • Checkpoint inhibitors (anti PD-1/PD-L1) are approved for second-line treatment of recurrent or metastatic disease, showing benefits in overall survival and quality of life.

Purpose of the Study:

  • To provide an overview of the current landscape of immunotherapy for head and neck squamous cell cancer as of 2018.
  • To highlight the importance of identifying predictive biomarkers for immunotherapy response.

Main Methods:

  • Review of current clinical studies and approved therapies.
  • Discussion of ongoing research combining immunotherapy with other treatments like chemotherapy and radiotherapy.

Main Results:

  • Checkpoint inhibitors (anti PD-1/PD-L1) demonstrate efficacy in recurrent or metastatic head and neck cancer.
Keywords:
BiomarkersBiomarqueursCarcinomeCheckpoint inhibitorsClinical trialsEssais cliniquesHead and neckImmunotherapyImmunothérapieInhibiteurs decarcinomacheckpointet cousquamous cellépidermoïde tête

Related Experiment Videos

  • Ongoing trials are exploring various combinations of immunotherapies and standard treatments.

    • Conclusions:

    • Immunotherapy represents a significant advancement in treating head and neck cancers.
    • The development of robust biomarkers is essential to optimize patient selection and improve the risk-benefit balance of immunotherapy.